Trials / Completed
CompletedNCT02248714
The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes
A 4-week, Single-center, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Glucerna SR Using Continuous Glucose Monitoring System(CGMS) in Chinese Drug-naïve Subjects With Type 2 Diabetes
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the effect of Glucerna SR treating newly-diagnosed type 2 diabetes patients (NDM) on glycemic stability, with the application of CGMS (continuous glucose monitoring system) and to further realize the safety and effect of Glucerna SR on daily and day-to-day amplitude of blood glucose fluctuation.
Detailed description
Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response. About 24% of the total energy provided by Glucerna SR is due to monounsaturated fatty acids, which can help keep good metabolic state in accordance with the recommendations of the American Heart Association. The aim of the study is to evaluate the effect of Glucerna SR treating newly-diagnosed type 2 diabetes patients (NDM) on glycemic stability, with the application of CGMS (continuous glucose monitoring system) and to further realize the safety and effect of Glucerna SR consumed as a meal replacement at breakfast meal on daily and day-to-day amplitude of blood glucose fluctuation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Glucerna SR | Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response. |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2018-06-01
- Completion
- 2018-12-01
- First posted
- 2014-09-25
- Last updated
- 2019-07-01
- Results posted
- 2019-07-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02248714. Inclusion in this directory is not an endorsement.